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Introduction
The recMAGE-A3 protein has been administered intra-
muscularly (IM) with immunostimulant AS15 as an
experimental immunotherapeutic. AS15 contains 3-O-
desacyl-4’-monophosphoryl lipid A (MPL), QS-21, CpG
7909 and liposome. This MAGE-A3/AS15 immunothera-
peutic has not been studied for intradermal (ID) or subcu-
taneous (SC) use. A clinical trial (NCT01425749) was
initiated to test the hypotheses that ID/SQ administration
is safe and may induce CD4+ and CD8+ T cell responses
to MAGE-A3.
Patients and methods
Twenty-five eligible patients with resected stage IIB-IV
MAGE-A3+ melanoma were randomized to 2 arms, trea-
ted with MAGE-A3/AS15 Immunotherapeutic IM (Arm
A, n = 13) or ID/SC (Arm B, n = 12). Adverse events
(CTCAE 4) were recorded. Antibody (Ab) responses to
MAGE-A3 protein were assessed by ELISA assay. T cell
responses were assessed by flow cytometry after intracellu-
lar cytokine staining (ICS) for multifunctional CD4+ and
CD8+ responses to overlapping MAGE-A3 peptides, assay-
ing lymphocytes from peripheral blood (PBMC) and senti-
nel immunized node (SIN), after one in vitro stimulation.
Results
In both arms, the recMAGE-A3/AS15 immunotherapeutic
was well-tolerated, with only one grade 3 treatment-related
adverse event (hyperglycemia, Arm B), and no grade 4 or
5 events. Grade 2 injection site reactions were observed
in 10 patients in Arm A and 7 in Arm B (P > 0.3). Ab
responses were detected in all patients, most with high
titers persisting at least 6 months, without difference
between arms. Preliminary T cell data are that multifunc-
tional (IFNg and TNFa) CD4+ T cell responses to MAGE-
A3 were detected in 64% of patients (54% A; 75% B;
Table 1). Multifunctional CD8+ T cell responses were
evident in 20% of patients (8% A, 33% B). CD4+ responses
were higher magnitude in SIN than in PBMC.
Conclusion
Safety profiles were comparable for ID/SC and IM
administration of the MAGE-A3/AS15 immunotherapeu-
tic, which induced high-titer Ab, multifunctional CD4+
Th1 responses, and CD8+ responses when administered
by either route. Immune responses were more readily
detected in the SIN than in PBMC. These pilot data
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Table 1 Multifunctional (IFNg and TNFa) T cell responses
to MAGE-A3
% of CD4+ T cells % of CD8+ T cells
(90% CI) (90% CI)
SIN PBMC Either SIN PBMC Either
Arm A 31% 31% 54% 0% 8% 8%
(11, 58) (11, 58) (29, 78) (0, 21) (0, 32) (0, 32)
Arm B 64% 50% 75% 18% 25% 33%
(35, 86) (25, 75) (47, 93) (3, 47) (7, 53) (12, 61)
Total 46% 40% 64% 8% 16% 20%
(28, 64) (24, 58) (46, 80) (2, 24) (6, 33) (8, 38)
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support further investigation of ID/SC immunization with
antigen plus AS15 to support Th1 CD4+ responses and
CD8+ responses. Production of Th1 cytokines IFNg and
TNFa suggests the induced CD4+ responses may support
CD8+ T cells. Other forms of antigen (e.g.: long peptides)
may further support induction of CD8+ T cell responses
in combination with AS15.
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